WO2014122575A3 - Fatty acid conjugates for the treatment of inflammation and metabolic diseases - Google Patents

Fatty acid conjugates for the treatment of inflammation and metabolic diseases Download PDF

Info

Publication number
WO2014122575A3
WO2014122575A3 PCT/IB2014/058775 IB2014058775W WO2014122575A3 WO 2014122575 A3 WO2014122575 A3 WO 2014122575A3 IB 2014058775 W IB2014058775 W IB 2014058775W WO 2014122575 A3 WO2014122575 A3 WO 2014122575A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
inflammation
treatment
pain
diseases
Prior art date
Application number
PCT/IB2014/058775
Other languages
French (fr)
Other versions
WO2014122575A2 (en
Inventor
Mahesh Kandula
Original Assignee
Cellixbio Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellixbio Private Limited filed Critical Cellixbio Private Limited
Publication of WO2014122575A2 publication Critical patent/WO2014122575A2/en
Publication of WO2014122575A3 publication Critical patent/WO2014122575A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/20—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Abstract

The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III; and methods for treating or preventing inflammation and metabolic diseases, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes, insulin resistance, hyperglycemia, neuropathic pain, hypertriglyceridemia, arthritis, autoimmune diseases, pain, chronic pain, acute inflammation, chronic aneurysm, low HDL, lipid diseases, angina, atherosclerosis, cerebrovascular accident (stroke), cerebrovascular disease, congestive heart failure, coronary artery disease, myocardial infarction.
PCT/IB2014/058775 2013-02-08 2014-02-04 Fatty acid conjugates for the treatment of inflammation and metabolic diseases WO2014122575A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN550/CHE/2013 2013-02-08
IN550CH2013 2013-02-08

Publications (2)

Publication Number Publication Date
WO2014122575A2 WO2014122575A2 (en) 2014-08-14
WO2014122575A3 true WO2014122575A3 (en) 2017-03-23

Family

ID=51300219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058775 WO2014122575A2 (en) 2013-02-08 2014-02-04 Fatty acid conjugates for the treatment of inflammation and metabolic diseases

Country Status (1)

Country Link
WO (1) WO2014122575A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883158B (en) * 2015-12-15 2019-08-23 中国科学院广州生物医药与健康研究院 Biodegradable amino lipids class compound and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
WO2011028689A1 (en) * 2009-09-01 2011-03-10 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100184730A1 (en) * 2008-07-08 2010-07-22 Vu Chi B Fatty Acid Acylated Salicylates and Their Uses
WO2011028689A1 (en) * 2009-09-01 2011-03-10 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011106688A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Bis-fatty acid conjugates and their uses

Also Published As

Publication number Publication date
WO2014122575A2 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
NZ737380A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2015017813A3 (en) Inhibitors of the farnesoid x receptor and uses in medicine
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
RU2016135543A (en) NEW DERIVATIVES OF INSULIN AND THEIR APPLICATION IN MEDICINE
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2008029217A3 (en) Dipeptidyl peptidase iv inhibitors
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
MX2018000012A (en) Compositions and methods for diagnosis and treatment of inflammation.
WO2016068453A8 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014122575A3 (en) Fatty acid conjugates for the treatment of inflammation and metabolic diseases
NZ729455A (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014080307A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2014195810A3 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014068506A3 (en) Compositions and methods for the treatment of autoimmune diseases
WO2013167995A3 (en) Compositions and methods for the treatment of hyperglycemia
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
CY1116484T1 (en) PHARMACEUTICAL COMPOSITIONS OF SYNCROMINATED WITH SUGAR ALCOHOLS
WO2014184723A3 (en) Compositions and methods for the treatment of cardiovascular diseases and lipid disorders

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14749695

Country of ref document: EP

Kind code of ref document: A2